UCB BIOPHARMA financials
UCB BIOPHARMA
Country: BE Reporting currency: EUR Latest annual report: 2022-12-31
LEI:
21380029O1RSZIAVOR95 Financial statements
(EUR, as reported — unscaled; 110 line items across 2 annual periods)
| Line item | 2022 | 2021 |
|---|---|---|
| Income statement | ||
| Revenue | €5.52B | €5.78B |
| Cost of sales | €1.67B | €1.44B |
| Gross profit | €3.84B | €4.34B |
| Operating profit (EBIT) | €585.0M | €1.28B |
| Finance costs | €112.0M | €138.0M |
| Profit before tax | €511.0M | €1.23B |
| Income tax expense | €91.0M | €170.0M |
| Profit for the year | €418.0M | €1.06B |
| — attributable to owners | €418.0M | €1.06B |
| Total comprehensive income | €913.0M | €1.34B |
| Per share | ||
| Basic EPS | €2.20 | €5.60 |
| Diluted EPS | €2.14 | €5.45 |
| Free cash flow / share | €4.44 | €6.55 |
| Cash flow statement | ||
| Cash generated from operations | €1.23B | €1.68B |
| Net cash from operating activities | €1.12B | €1.55B |
| Income taxes paid | €107.0M | €126.0M |
| Net cash from investing activities | -€1.58B | -€487.0M |
| Purchase of PP&E (capex) | €252.0M | €282.0M |
| Purchase of intangibles | €119.0M | €211.0M |
| Net cash from financing activities | €70.0M | -€1.12B |
| Dividends paid | €247.0M | €240.0M |
| Proceeds from borrowings | €1.02B | €0 |
| Repayments of borrowings | €284.0M | €512.0M |
| Lease liability payments | €46.0M | €40.0M |
| Net change in cash | -€391.0M | -€53.0M |
| Balance sheet | ||
| Total assets | €15.87B | €14.21B |
| Non-current assets | €12.56B | €10.50B |
| Property, plant & equipment | €1.43B | €1.27B |
| Intangible assets & goodwill | €5.34B | €5.17B |
| Current assets | €3.30B | €3.71B |
| Inventories | €907.0M | €878.0M |
| Trade & other receivables | €1.05B | €1.24B |
| Cash & equivalents | €899.0M | €1.26B |
| Total equity | €9.06B | €8.39B |
| — attributable to owners | €9.06B | €8.39B |
| Non-current liabilities | €3.69B | €3.00B |
| Current liabilities | €3.11B | €2.82B |
| Trade & other payables | €2.49B | €2.56B |
| Deferred tax liabilities | €377.0M | €191.0M |
| Derived metrics | ||
| Free cash flow | €867.0M | €1.27B |
| Operating margin | 10.6% | 22.2% |
| Net margin | 7.6% | 18.3% |
| Return on equity | 4.6% | 12.6% |
| Cash conversion ratio | 2.68× | 1.47× |
| Capex coverage | 4.44× | 5.51× |
| Other reported items | ||
| Basic Earnings Loss Per Share From Continuing Operations | €2.21 | €5.59 |
| Basic Earnings Loss Per Share From Discontinued Operations | €-0.01 | €0.01 |
| Cash and Cash Equivalents If Different From Statement of Financial Position | €859.0M | €1.24B |
| Cash Flows From Losing Control of Subsidiaries Or Other Businesses Classified As Investing Activities | €0 | €15.0M |
| Cash Flows From Used In Financing Activities Continuing Operations | €70.0M | -€1.12B |
| Cash Flows From Used In Financing Activities Discontinued Operations | €0 | €0 |
| Cash Flows From Used In Investing Activities Continuing Operations | -€1.58B | -€487.0M |
| Cash Flows From Used In Investing Activities Discontinued Operations | €0 | €0 |
| Cash Flows From Used In Operating Activities Continuing Operations | €1.12B | €1.55B |
| Cash Flows From Used In Operating Activities Discontinued Operations | €0 | €0 |
| Cash Flows Used In Obtaining Control of Subsidiaries Or Other Businesses Classified As Investing Activities | €1.21B | €0 |
| Comprehensive Income Attributable To Owners of Parent | €913.0M | €1.34B |
| Current Bonds Issued and Current Portion of Noncurrent Bonds Issued | €174.0M | €0 |
| Current Loans Received and Current Portion of Noncurrent Loans Received | €88.0M | €55.0M |
| Current Tax Assets Current | €78.0M | €51.0M |
| Current Tax Liabilities Current | €50.0M | €31.0M |
| Current Tax Liabilities Noncurrent | €126.0M | €139.0M |
| Deferred Tax Assets | €756.0M | €692.0M |
| Diluted Earnings Loss Per Share From Continuing Operations | €2.15 | €5.44 |
| Diluted Earnings Loss Per Share From Discontinued Operations | €-0.01 | €0.01 |
| Dividends Paid To Equity Holders of Parent Classified As Financing Activities | €247.0M | €240.0M |
| Dividends Proposed Or Declared Before Financial Statements Authorised For Issue But Not Recognised As Distribution To Owners | €252.0M | — |
| Dividends Proposed Or Declared Before Financial Statements Authorised For Issue But Not Recognised As Distribution To Owners Per Share | — | €1.33 |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | €6.0M | -€7.0M |
| Equity and Liabilities | €15.87B | €14.21B |
| Expense of Restructuring Activities | €42.0M | €21.0M |
| Finance Income | €38.0M | €80.0M |
| General and Administrative Expense | €225.0M | €208.0M |
| Income Tax Relating To Components of Other Comprehensive Income That Will Be Reclassified To Profit Or Loss | €13.0M | -€33.0M |
| Income Tax Relating To Components of Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss | €13.0M | €10.0M |
| Increase Decrease Through Changes In Ownership Interests In Subsidiaries That Do Not Result In Loss of Control | — | €0 |
| Increase Decrease Through Sharebased Payment Transactions | €70.0M | €75.0M |
| Increase Decrease Through Transfers and Other Changes Equity | €0 | €0 |
| Increase Decrease Through Treasury Share Transactions | -€58.0M | -€65.0M |
| Intangible Assets Other Than Goodwill | €4.82B | €3.16B |
| Interest Paid Classified As Financing Activities | €74.0M | €63.0M |
| Interest Received Classified As Operating Activities | €28.0M | €17.0M |
| Liabilities | €6.80B | €5.82B |
| Noncurrent Assets Or Disposal Groups Classified As Held For Sale | €0 | €6.0M |
| Noncurrent Payables | €119.0M | €86.0M |
| Noncurrent Portion of Noncurrent Bonds Issued | €549.0M | €816.0M |
| Noncurrent Portion of Noncurrent Loans Received | €2.09B | €1.25B |
| Noncurrent Provisions For Employee Benefits | €162.0M | €315.0M |
| Other Adjustments For Noncash Items | €752.0M | €239.0M |
| Other Adjustments For Which Cash Effects Are Investing Or Financing Cash Flow | €58.0M | €41.0M |
| Other Adjustments To Reconcile Profit Loss | €91.0M | €170.0M |
| Other Comprehensive Income | €495.0M | €286.0M |
| Other Comprehensive Income Before Tax Cash Flow Hedges | €104.0M | -€140.0M |
| Other Comprehensive Income Before Tax Exchange Differences On Translation | €272.0M | €280.0M |
| Other Comprehensive Income Before Tax Financial Assets Measured At Fair Value Through Other Comprehensive Income | €0 | €26.0M |
| Other Comprehensive Income Before Tax Gains Losses On Remeasurements of Defined Benefit Plans | €145.0M | €97.0M |
| Other Longterm Provisions | €171.0M | €188.0M |
| Other Operating Income Expense | €216.0M | €162.0M |
| Other Revenue | €292.0M | €227.0M |
| Other Shortterm Provisions | €191.0M | €83.0M |
| Payments To Acquire Or Redeem Entitys Shares | €42.0M | €60.0M |
| Proceeds From Sales of Investments Other Than Investments Accounted For Using Equity Method | €19.0M | €9.0M |
| Proceeds From Sales of Property Plant and Equipment Classified As Investing Activities | €0 | €1.0M |
| Profit Loss From Continuing Operations | €420.0M | €1.06B |
| Profit Loss From Discontinued Operations | -€2.0M | €3.0M |
| Purchase of Investments Other Than Investments Accounted For Using Equity Method | €17.0M | €19.0M |
| Repayments of Bonds Notes and Debentures | €262.0M | €204.0M |
| Research and Development Expense | €1.67B | €1.63B |
| Revenue From Sale of Goods | €5.14B | €5.47B |
| Sales and Marketing Expense | €1.49B | €1.35B |
Methodology
Every line item above is a fact tagged in UCB BIOPHARMA's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.